Skip to main content

Table 1 Demographic criteria of the patients

From: Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin's Lymphoma

Variable Patients with Complete Remission (CR) N (%) Patients with Relapsed Disease (RD) N (%)
Number 96 34
Age at diagnosis   
Median 31 27.5
15-20 16 (16.7) 17 (50)
21-30 32 (33.3) 5 (14.7)
31-40 18 (18.8) 5 (14.7)
> 40 30 (31.2) 8 (20.6)
Gender   
Males 50 (52.1) 21 (61.8)
Females 46 (47.9) 13 (38.2)
Stage   
Early stages (I &II) 41 (42.7) 20 (58.8)
Advanced stages (III & IV) 38 (39.6) 12 (35.3)
Missed data 17 (17.7) 2 (5.9)
Presence of B symptoms   
Yes 54 (56.3) 19 (55.9)
No 31 (32.3) 13 (38.2)
Missed data 11 (11.4) 2 (5.9)
Bone marrow involvement   
Yes 5 (5.2) 4 (11.8)
No 91 (94.8) 30 (88.2)
Histology   
Nodular sclerosis 46 (47.9) 16 (47.1)
Mixed cellularity 25 (26) 6 (17.6)
Lymphocyte rich 5 (5.2) 3 (8.8)
Lymphocyte depleted 4 (4.2) 0 (0)
Nodular lymphocyte predominance 1 (1) 5 (14.7)
Classical 7 (7.3) 4 (11.8)
Missed data 8 (8.3) -
Chemotherapy regimen ABVD: All the patients ABVD: Initially all the patients at relapse: ICEa (8), ESHAPb (8), COPPc (3), ABVDd (8), Others: (7).
Number of ABVD cycles   
< 6 cycles 10 (10.4) 6 (17.6)
6 cycles 77 (80.2) 22 (64.7)
> 6 cycles 9 (9.4) 5 (14.7)
  1. aAdriamycin, Bleomycin, Vinblastine, Decarbazine; bIfosfamide, Carboplatin, Etoposide; cEtoposide, Cisplatin, Cytarabine, Methylprednisolone; dCyclophosphamide, Vincristine, Prednisolone, Procarbazine.